By Josh Beckerman
Clarus Therapeutics Holdings Inc. shares were recently up 49% to $2.16.
On Tuesday, Clarus shares rose 22% after the company said it would present new data for Jatenzo, a testosterone capsule, on Saturday at the Androgen Society's annual meeting. Two abstracts will be presented, including one that discusses a comparison with AndroGel 1%.
Write to Josh Beckerman at josh.beckerman@wsj.com
$(END)$ Dow Jones Newswires
April 20, 2022 14:46 ET (18:46 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.